A method of generating an antibody and cellular immune response against a Plasmodium in a primate, comprising administering at least 10.sup.3 genetically modified live Plasmodium to the primate, wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein, to thereby induce an antibody and cellular immune response against the Plasmodium in the primate. In some embodiments at least 10.sup.4 genetically modified live Plasmodium is administered to the primate. An immunogenic composition for administration to a primate, comprising a at least 10.sup.3 genetically modified live Plasmodium wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein; and at least one pharmaceutically acceptable excipient and/or support. In some embodiments the immunogenic composition comprises at least 10.sup.3 genetically a modified live Plasmodium.

A method of generating an antibody and cellular immune response against a Plasmodium in a primate, comprising administering at least 10.sup.3 genetically modified live Plasmodium to the primate, wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein, to thereby induce an antibody and cellular immune response against the Plasmodium in the primate. In some embodiments at least 10.sup.4 genetically modified live Plasmodium is administered to the primate. An immunogenic composition for administration to a primate, comprising a at least 10.sup.3 genetically modified live Plasmodium wherein the genetically modified live Plasmodium is a species selected from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi, Plasmodium coatneyi, Plasmodium cynomolgi, and Plasmodium simium, and wherein the genetically modified live Plasmodium does not produce functional histamine releasing factor (HRF) protein; and at least one pharmaceutically acceptable excipient and/or support. In some embodiments the immunogenic composition comprises at least 10.sup.3 genetically a modified live Plasmodium.

A method of treating or preventing a microbial infection in a subject is described. The method includes contacting a microorganism within the subject with a composition comprising one or more species of amoebae of the genus Willaertia. Antibiotic wound dressings and kits for providing amoeba for treatment or prevention of microbial infection in a subject are also described.

A method of treating or preventing a microbial infection in a subject is described. The method includes contacting a microorganism within the subject with a composition comprising one or more species of amoebae of the genus Willaertia. Antibiotic wound dressings and kits for providing amoeba for treatment or prevention of microbial infection in a subject are also described.

The liquid biological antifungal product containing the Pythium oligandrum microorganism containing a stabilized suspension of the Pythium oligandrum microorganism contains 0.05 to 10.0% weight culturing biomass of the Pythium oligandrum microorganism with content of cultivation medium, cell forms of this microorganism and substances produced by this microorganism and 90.0 to 99.95% weight stabilizer, where-by the pre-determined number of dormant oospores in 1 ml of this liquid biological anti-fungal product is, following normal standardization, between 1×10.sup.3 and 2×10.sup.7. The liquid biological antifungal product containing the Pythium oligandrum microorganism containing a stabilized suspension of the Pythium oligandrum microorganism contains 0.05 to 10.0% weight culturing biomass of the Pythium oligandrum microorganism with content of cultivation medium, cell forms of this microorganism and substances produced by this microorganism; and 79.77 to 99.95% weight stabilizer, and the remainder, up to 100% weight, a minimum of one modifying/application substance from a group including filling, aroma and vitamin; whereby the pre-determined number of dormant oospores in 1 ml of this liquid biological antifungal product is, following normal standardization, between 2.5×10.sup.4 and 1.0×10.sup.6. The Pythium oligandrum microorganism is the Pythium oligandrum Dreschler ATTC 38472 strain, which was deposited in the Czech Collection of Microorganisms (CCM) at Masaryk University in Brno under the appellation of Pythium oligandrum M1. The stabilizer may be water, a salt solution, oil or a concentrated solution of osmolytes. The method of production of this liquid biological antifungal product is claimed.

Provided are nucleic acid constructs, Toxoplasma comprising same, pharmaceutical compositions comprising same and methods using same for delivering a protein-of-interest to a tissue-of-interest of a subject, such as the CNS and further treating a pathology which is treatable by administration of a therapeutic polypeptide in a central nervous system of the subject.

Provided are nucleic acid constructs, Toxoplasma comprising same, pharmaceutical compositions comprising same and methods using same for delivering a protein-of-interest to a tissue-of-interest of a subject, such as the CNS and further treating a pathology which is treatable by administration of a therapeutic polypeptide in a central nervous system of the subject.

The present application relates to beta-1,3-glucan and uses thereof to modulate immunity in the human body. Also provided are methods for treatment and/or prevention of high cholesterol, diabetes, and allergies. Also provided are methods for treatment and/or prevention of intestinal inflammation.

The present application relates to beta-1,3-glucan and uses thereof to modulate immunity in the human body. Also provided are methods for treatment and/or prevention of high cholesterol, diabetes, and allergies. Also provided are methods for treatment and/or prevention of intestinal inflammation.

The present invention is directed to isolated microorganisms as well as strains and mutants thereof, biomasses, microbial oils, compositions, and cultures; methods of producing the microbial oils, biomasses, and mutants; and methods of using the isolated microorganisms, biomasses, and microbial oils.